Aktis Oncology, Inc., a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted ...

Bildnachweis: ITM. The radiopharmaceutical industry is entering a new era. Driven by clinical breakthroughs, regulatory ...

Politico reported late Monday that Transportation Secretary and interim NASA head Duffy will announce this week expedited ...

BWX Technologies reached a record high, leading nuclear-related stocks on reports the US Secretary of Transportation is set ...

(ST. JOSEPH, Mo) Mosaic Life Care is advancing its cancer treatment for patients with metastatic prostate cancer. PLUVICTO is ...

Average selling prices of Illuccix will likely decrease when its transitional pass-through payment status expires in 2025.

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch of novel therapies such as BXCL701, Peluntamig, ...

Androgen deprivation therapy (ADT) – also called hormone therapy - remains central to prostate cancer care, but emerging treatments like radioisotopes and antibody therapies may reduce reliance on ...